FDA Removes HRT Black Box Warning: What It Means

For more than two decades, hormone replacement therapy (HRT) carried the FDA's most severe warning label: the black box warning. This label, reserved for drugs with the most serious safety concerns, shaped medical practice, frightened patients, and kept millions of women from accessing treatment for debilitating menopausal symptoms.

In 2025, the FDA removed this warning. The decision reflects a fundamental re-evaluation of the evidence on hormone therapy, its risks, and its benefits. Understanding what changed, and what didn't, matters for every woman navigating menopause.

A brief history: how the black box got there

To understand the significance of the removal, you need to understand how the warning got there in the first place.

Before 2002: the era of confidence

Through the 1990s, hormone therapy was widely prescribed. Millions of women used it not just for symptom relief but for perceived cardiovascular protection and disease prevention. HRT was considered safe and beneficial, and it was one of the most commonly prescribed medications in the United States.

2002: the WHI bombshell

The Women's Health Initiative (WHI) was a large randomized controlled trial designed to provide definitive evidence about hormone therapy. In July 2002, researchers stopped one arm of the trial (estrogen plus progestin in women with a uterus) early because of safety concerns. The headlines were alarming: increased risks of breast cancer, heart disease, stroke, and blood clots.

The reaction was swift and dramatic. HRT prescriptions dropped by 50% or more. The FDA added the black box warning. Doctors stopped prescribing hormone therapy. Women who were taking it stopped abruptly, often without medical guidance. An entire generation of clinicians was trained to view hormone therapy with suspicion.

2002-2020: the slow correction

In the years following the WHI publication, the data was reanalyzed extensively. Several critical nuances emerged that had been lost in the initial headlines:

• Age matters enormously. The average age of participants in the WHI was 63. Most women were more than a decade past menopause when they started hormone therapy. Subsequent analyses showed that the risks identified in the WHI were concentrated in older women who started HRT late, while younger women (those within 10 years of menopause onset) showed a very different risk profile.
• The "timing hypothesis." Research increasingly supported what became known as the timing hypothesis: hormone therapy started near the onset of menopause appears to be protective for cardiovascular health, while therapy started many years later may increase risk. This distinction was absent from the original WHI reporting.
• Type of hormone matters. The WHI used oral conjugated equine estrogens and medroxyprogesterone acetate (a synthetic progestin). Subsequent research suggested that transdermal estrogen (patches) carries lower risks for blood clots and stroke, and that micronized progesterone may have a more favorable safety profile than synthetic progestins.
• Estrogen-only therapy was different. The WHI's estrogen-only arm (for women without a uterus) actually showed a reduced risk of breast cancer and no increase in cardiovascular events. This result was often overlooked in the general alarm.
• Absolute risk vs. relative risk. The WHI risks, when expressed in absolute terms, were small. For example, the increased breast cancer risk amounted to approximately 1 additional case per 1,000 women per year. The headlines reported relative risk increases, which sounded much more alarming.

What the FDA's removal means

The FDA's decision to remove the black box warning acknowledges that the totality of evidence no longer supports the most extreme safety warning. This does not mean that hormone therapy is risk-free. It means that the risks, when properly understood in context (age at initiation, type of hormone, route of administration, individual risk factors), do not rise to the level that warrants a black box designation.

What the removal does

• Signals that hormone therapy, when used appropriately, has an acceptable safety profile for the intended population
• May reduce the stigma and fear that have kept women and providers from considering HRT
• Aligns FDA labeling more closely with the current scientific consensus and the positions of major medical societies (NAMS, IMS, Endocrine Society)
• May encourage updated clinical education for providers who were trained during the peak of HRT avoidance

What the removal does not do

• It does not mean hormone therapy is appropriate for everyone
• It does not eliminate all risks associated with HRT
• It does not change the recommendation for individualized decision-making
• It does not mean women should start HRT without consulting a healthcare provider

The human cost of the black box era

The two decades of the black box warning had real consequences. Research has documented several effects:

• Untreated symptoms. The New England Journal of Medicine estimated in 2016 that 75% of symptomatic menopausal women were not receiving treatment. Many women suffered from severe hot flashes, sleep disruption, vaginal atrophy, and mood changes without relief because they or their providers were afraid of hormone therapy.
• Increased fractures. As HRT use declined, osteoporotic fractures increased in older women who might have benefited from hormone therapy's bone-protective effects.
• Provider knowledge gaps. Multiple surveys have documented that medical education on menopause is inadequate. A 2017 survey published in Menopause found that only 20% of OB-GYN residency programs had a formal menopause curriculum. The black box warning contributed to an environment where providers were more comfortable avoiding hormone therapy than prescribing it.
• Rise of unregulated alternatives. As women sought relief outside of conventional HRT, the market for unregulated "bioidentical" hormone products, supplements, and unproven remedies expanded substantially.

What the current evidence says about HRT

The scientific consensus, as reflected by major medical organizations, can be summarized as follows:

For whom is HRT most appropriate?

• Women with moderate to severe vasomotor symptoms (hot flashes, night sweats)
• Women under 60 or within 10 years of menopause onset
• Women with early menopause (before age 45), where HRT is recommended at least until the average age of natural menopause
• Women with genitourinary syndrome of menopause (vaginal dryness, painful intercourse)
• Women at elevated risk of osteoporosis who cannot take other bone-protective medications

Benefits supported by evidence

• Effective relief of hot flashes and night sweats (the primary indication)
• Improvement in sleep quality when disrupted by vasomotor symptoms
• Prevention of bone loss and reduction in fracture risk
• Treatment of vaginal dryness and genitourinary symptoms
• Potential cardiovascular benefit when initiated near menopause onset (timing hypothesis)
• Improvement in mood and quality of life

Risks that remain

• Breast cancer: Combined estrogen-progestogen therapy may modestly increase breast cancer risk after 3-5 years of use. Estrogen-only therapy does not appear to increase risk and may reduce it.
• Blood clots: Oral estrogen increases the risk of venous thromboembolism. Transdermal estrogen (patches) does not appear to carry this risk.
• Stroke: Oral estrogen may slightly increase stroke risk, particularly in women over 60. Again, transdermal delivery appears to mitigate this.
• Endometrial cancer: Unopposed estrogen in women with a uterus increases endometrial cancer risk. This is why progestogen is always added for women who have not had a hysterectomy.

What this means for you personally

If you are currently taking hormone therapy, the removal of the black box warning is reassuring but does not change your management plan. Continue working with your provider to ensure your current regimen is appropriate for your individual situation.

If you have been avoiding hormone therapy due to fear, this is a good time to revisit that decision with your provider. The conversation should include:

1. Your symptoms. How severe are they? How much do they affect your quality of life?
2. Your age and time since menopause. The benefit-risk ratio is most favorable for women under 60 or within 10 years of menopause onset.
3. Your individual risk factors. Personal and family history of breast cancer, blood clots, stroke, and cardiovascular disease all factor into the decision.
4. Type and route of administration. Transdermal estrogen and micronized progesterone generally have the most favorable safety profile.
5. Duration. There is no arbitrary time limit on HRT. The decision to continue should be reviewed periodically based on ongoing symptoms and risk assessment.

The broader significance

The removal of the HRT black box warning is more than a regulatory update. It represents a correction of a two-decade-long overcorrection. The initial WHI findings were important, but their misinterpretation and overapplication caused significant harm: women suffered unnecessarily, clinical practice shifted away from evidence-based treatment, and a generation of providers was undertrained in menopause management.

The lesson extends beyond hormone therapy. It is a reminder that health communication matters enormously. How risks are presented, the difference between relative and absolute risk, the importance of context and nuance, these affect millions of individual treatment decisions.

For women navigating menopause today, the message is cautiously encouraging: hormone therapy, when used appropriately by the right patients at the right time, is a safe and effective treatment option. The evidence supports this, and the FDA's labeling now reflects it.

The bottom line

The removal of the black box warning from HRT marks a significant shift in how hormone therapy is officially regarded. It does not make HRT risk-free, and it does not make it appropriate for everyone. What it does is move the conversation from fear to informed decision-making.

If menopausal symptoms are affecting your quality of life, you deserve a thorough, evidence-based conversation with your provider about all your options, including hormone therapy. The era of reflexive avoidance of HRT is over. The era of individualized, informed treatment has arrived.